Navigation Links
Orexigen(R) Therapeutics to Speak at J.P. Morgan Healthcare Conference
Date:1/6/2009

SAN DIEGO, Jan. 6 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the 27th Annual J.P. Morgan Healthcare Conference. The details are as follows:

    Date:  Monday, January 12, 2009
    Time:  8:00 a.m. - 8:30 a.m. Pacific
    Location: Westin St. Francis, San Francisco, California

    Webcast link:
http://metameetings.com/webcasts/jpmorgan/healthcare09/directlink?ticker=OREX

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead combination product candidates are Contrave(R), which is in Phase 3 clinical trials, and Empatic(TM), which is in the later stages of Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. Further information about the company can be found at http://www.orexigen.com.


'/>"/>
SOURCE Orexigen Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Orexigen(R) Therapeutics Announces Webcast of Third Quarter Financial Results on November 6, 2008
2. Prime Therapeutics Hires Steven Blumenfield as Chief Marketing Officer
3. Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US
4. Pain Therapeutics Receives Complete Response Letter From FDA for REMOXY(R)
5. Prime Therapeutics Announces Blue Cross and Blue Shield of Montana as a Pharmacy Benefit Services Client
6. Agile Therapeutics Abstracts on Lead Product, AG200-15 Accepted by ACOG
7. Cell Therapeutics, Inc. to Offer to Repurchase up to $124 Million of Its Notes
8. Horizon Therapeutics announces 2 pivotal HZT-501 Phase 3 trials meet primary endpoints
9. Transition Therapeutics Announces Dates for Upcoming Corporate Events
10. Taligen Therapeutics Advances Corporate Growth Plan with Appointment of Jeffrey T. Walsh as Chief Business Officer
11. Precision Therapeutics Secures $43 Million in Venture Capital Funding
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The Patient Advocacy Community of The Beryl ... 2017 Ruth Ravich Patient Advocacy Award in recognition of her extraordinary contributions ... with the award at The Beryl Institute’s annual Patient Experience Conference on ...
(Date:4/21/2017)... (PRWEB) , ... April 21, 2017 , ... Alive ... people who wish to overcome their mental health struggles. The Alive team uses ... LeBouthillier says: “Our approach in dealing with a mental health struggle is based on ...
(Date:4/21/2017)... Ramon, CA (PRWEB) , ... April 21, 2017 , ... ... might not understand the estate planning process, or where to even begin. “Now more ... unresolved if you are to properly protect yourself and your family,” said attorney Lisa ...
(Date:4/21/2017)... ... April 21, 2017 , ... During April 21-23, Super-Sod will join the ... festival offers entertainment for everyone — from the avid gardener to the landscape admirer ... high quality event held in a grand venue, and we are certainly looking forward ...
(Date:4/21/2017)... ... April 21, 2017 , ... MiracleFeet announced today ... years to help end the disability caused by untreated clubfoot in low-income countries. ... Global Clubfoot Initiative to end disability caused by clubfoot worldwide. , ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... BOSTON , April 20, 2017   ZappRx, Inc ... the specialty drug prescribing process, today announced it closed $25 ... Fund, a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included ... A round in 2014, and GV (formerly Google ...
(Date:4/20/2017)... 20, 2017 NeuroVive Pharmaceutical AB (Nasdaq ... positive preclinical results demonstrating anti-fibrotic effects with ... steatohepatitis (NASH), in an additional well-validated experimental ... has previously shown similar anti-fibrotic effects in ... scientists present novel data demonstrating anti-fibrotic effects ...
(Date:4/19/2017)... 2017 The Mobile X-Ray product segment is the ... during the forecast period Mobile X-Ray segment is ... mobile X-Ray devices market, which is estimated to be valued ... a CAGR of 7% over the forecast period. Mobile X-Ray ... than US$ 100 Mn in 2017 over 2016. The segment,s ...
Breaking Medicine Technology: